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Comment on: ‘Trends in the lifetime risk of developing cancer in great Britain: comparison of risk for
those born from 1930 to 1960’—cancer predictions need more context
JL Oke*,1, BD Nicholson1 and B Shinkins1
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK
Sir,
Projections of lifetime risk and cancer incidence for the next 25 years
reported by Ahmad et al (2015) are alarming but probably realistic. In the last
30 years, the incidence of all cancers in the United Kingdom has risen from
293 cases per 100 000 persons in 1975 to 396 per 100 000 in 2011 (Cancer
Research UK, 2012), a rise of 35%. We were, however, surprised to such
limited discussion or analysis of cancer mortality trends over the equivalent
time period, which has fallen 21% since 1971 (Cancer Research UK, 2012).
There has been a steady and linear increase over time in cancer incidence
(Figure 1, solid black line). Extrapolating this trend forward (black dotted line)
using simple linear regression produces incidence rates that generate lifetime
and cumulative risks that are broadly in line with Ahmad et al’s more
sophisticated approach. Using the same method to extrapolate the trend in all-
cancer mortality (solid grey line) suggests that all-cancer mortality will
continue to decline (grey dashed line). In short, extrapolating current trends
forward sends incidence and mortality in different directions, and this
suggests a future in which cancer becomes more common but at the same time
more benign.
One explanation for detecting increasing levels of cancer on the scale
suggested by Ahmad et al without a concomitant increase in mortality is the
detection of disease that will not go on to cause symptoms or death:
‘overdiagnosis’ (Welch and Black, 2010). This was acknowledged as
contributory to the increased incidence in prostate cancer in relation to
PSA testing, yet similar trends can be seen for thyroid, kidney, melanoma
and breast cancer. Although it is methodologically challenging to take into
account the impact of over-diagnosis and its underlying causes, diagnostic
drift, increasing test sensitivity and changing competing mortality risks,
these are important considerations to note when interpreting incidence data
(Carter et al, 2015).
We call on the authors to publish their projected mortality rates to provide
greater context to these worrying figures. The public deserve clear information
about the drivers behind them, especially given the cumulative risk of over-
diagnosis in an ageing population.
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Figure 1. All-cancer incidence and mortality in the United Kingdom
from 1975 to 2011(solid lines) and projected incidence and mortality
(dashed lines).
Comment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for
recurrent glioblastoma’
Susannah Ellsworth*,1 and Stuart A Grossman2
1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA and 2Department of Oncology, Medicine, &
Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Sir,
In this manuscript, Dr Wong and colleagues observed that patients with
recurrent glioblastoma who underwent therapy with tumor treating
alternating electrical fields and were on higher doses of dexamethasone
had lower T-lymphocyte counts and shorter survival (Wong et al, 2015). The
investigators attributed these outcomes entirely to ‘global immunosuppres-
sion by dexamethasone’. In fact, this patient population receives three
therapies that are highly toxic to lymphocytes – glucocorticoids, radiation,
and temozolomide. Recent studies have demonstrated that 40% of patients
with newly diagnosed glioblastoma develop grade III and IV lymphopenia
with CD4 counts o200 cells mm 3 2 months after beginning radiation and
temozolomide (Grossman et al, 2011). This profound lymphopenia lasts for
over 1 year and on multivariate analysis is independently associated with
inferior survival. Treatment-induced lymphopenia has also been studied in
other solid tumors that are not treated with dexamethasone or temozolo-
mide; data from these studies strongly point to radiation as the primary
causative factor in treatment-induced lymphopenia. These studies reported
rates of lymphopenia that were very similar to those seen in glioblastoma
and again identified an association between treatment-induced lymphopenia
and survival in patients with pancreatic cancer, non-small cell lung cancer,
and breast cancer. (Balmanoukian et al, 2012; Campian et al, 2013; Wild
et al, 2013; Tang et al, 2014; Afghahi et al, 2015) Two hypotheses have been
advanced to explain this phenomenon. The first relates to the inadvertent
radiation of circulating lymphocytes (MacLennan and Kay, 1978; Yovino
et al, 2013). The second stems from observations that IL-7 levels are
inappropriately low in irradiated patients with severe treatment-related
lymphopenia (Ellsworth et al, 2014). We agree that immune status is an
important prognostic factor in patients with recurrent glioblastoma.
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